ER-positive tumour BC

Drug target for aggressive breast cancer found

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab.

The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers. 

Photo
This image shows a cluster of slow-cycling (AKT-low/Hes1-high) breast cancer cells (red) within a human ER+ primary breast tumor (cell nuclei in blue; rapidly cycling, AKT-high, cancer cells in green)

Image source: National Cancer Institute (NCI) / Dana-Farber Harvard Cancer Center at Massachusetts General Hospital

Around three quarters of women who have breast cancer have what are known as oestrogen receptor (ER) positive tumours. Some breast cancer cells have receptors that bind to the hormone oestrogen and depend on it to grow. Though anti-oestrogen drugs such as tamoxifen and fulvestrant are able to prevent reoccurrence in most of these breast cancers, tumours reoccur in 1 out of 4 cases. Many of the women relapse after several years, because some of the cancer cells remain after treatment.

The cells, called cancer stem cells, lay dormant in the body and cannot be targeted by anti-oestrogen therapies. Scientists have now found that cancer stem cells resistant to anti-oestrogen drugs express an immune system-related receptor called interleukin 1 receptor. The team found that a biological inhibitor of this receptor called Anakinra, used to treat rheumatoid arthritis, was able to reduce the ability of the cancer stem cells to form colonies in vitro.

However, further validation in animals and humans is required before the team to confirm if drugs targeting interleukin 1 receptor could be used as an effective treatment. The study, published in Stem Cell Reports, was funded by the Medical Research Council and Breast Cancer Now. Scientists from the Universities of Michigan, Liverpool and Edinburgh were closely involved in the work from the team in Manchester.

We hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy

Bruno Simões

Dr Simões said: “Resistance to anti-oestrogen therapies in breast cancer patients is a major problem and one which cancer scientists have been trying to address for many years. Many drugs have been investigated by scientists as a possible combination therapy taken with anti-oestrogen therapies and we are still searching for a solution for these patients. However, most of these drugs target actively dividing cells whereas we are trying to also target cells that are in a dormant state. So we hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy. There’s a very long way to go before we can say if this approach will help these women but we are excited by our findings.”


Source: University of Manchester

28.07.2020

Read all latest stories

Related articles

Photo

Triple-negative breast cancer

Target validation for drug development against aggressive breast cancer

At around 30.5 percent, breast cancer is the most common cancer among women in countries of the industrialized world. The number of cases has doubled since the 1980s: about 69,000 times a year women…

Photo

Stem cell regeneration

Drug accelerates recovery after chemo, radiation

A drug developed by US physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the…

Photo

New discovery

Cancer drugs promote stem cell properties of colorectal cancer

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH